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Inherited bleeding disorders are heterogeneous in aetiology and 
clinical presentation and may arise from platelet, blood vessel or 
clotting factor structural or functional abnormalities.[1] Haemophilia 
is the most common X-linked condition, affecting 1 in 5 000 and 
1 in 25 000 live male births for haemophilia A and B, respectively. [2] 
In South Africa (SA), with a population of 57 700 million people,[3] 
the expected number of people with haemophilia is 5 770, of 
whom only ~2 200 have been diagnosed.[4] Once diagnosed, 
haemophilia imposes a high disease and treatment burden on 
patients, caregivers, healthcare providers and the healthcare facilities 
involved in management. The disease burden includes unpredictable 
spontaneous acute bleeds as well as chronic complications of bleeds 
into the musculoskeletal system, muscle and soft tissues, which may 
be life or organ threatening or disabling.[5-8] The treatment burden 
is in part due to lifelong treatment for spontaneous and traumatic 
bleeds[9,10] with clotting factor concentrate (CFC) replacement therapy, 
administered by intravenous infusion and therefore requiring specific 
care processes and skills.
Current management of bleeds in haemophilia is by intravenous 
replacement of the deficient clotting factor to treat or prevent 
bleeding episodes.[11] Episodic treatment, the reactive modality, 
is associated with progressive deterioration of musculoskeletal 
structures, musculoskeletal function and quality of life.[12] The 
proactive alternative is prophylaxis, the standard of care in 
haemophilia, in which patients receive regular infusions of clotting 
factor to prevent bleed occurrence.[13,14] Replacement therapy, 
whether given episodically or prophylactically, may be delayed while 
patients are transported to healthcare facilities. This delay has been 
shown to result in complications of bleeds, which become more 
difficult to manage, delayed in their resolution, and associated with 
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Background. Optimal care of patients with inherited bleeding disorders requires that bleeding episodes are treated early, or still better 
prevented, through extension of patient care beyond hospital-based treatment to home-based therapy. In South Africa (SA), adoption of 
home therapy is variable, in part owing to lack of consensus among healthcare providers on what constitutes home therapy, which patients 
should be candidates for it, how it should be monitored, and what the barriers to home therapy are.
Objectives. To conduct a modified Delphi process in order to establish consensus on home therapy among haemophilia healthcare 
providers in SA.
Methods. Treaters experienced in haemophilia care were invited to participate in a consensus-seeking process conducted in three rounds. 
In round 1, provisional statements around home therapy were formulated as questions and collated in a structured list. In rounds 2 and 3, 
evolving versions of the questionnaire were administered to participants. Consensus was defined as ≥70% agreement among the participants.
Results. The panel composition included an equal number of physicians and non-physicians. The participation rate was 100% through all 
three consensus rounds. The group reached consensus for 92% of the statements. Consensus of 100% was reached on starting home therapy 
in paediatric patients, requiring all patients on home therapy to sign informed consent and indemnity, and providing round-the-clock 
support for patients on home therapy.
Conclusions. The home therapy consensus statements in this report have the potential to translate to policy on home therapy and to guide 
the initiation, practice and evaluation of home therapy programmes in SA.
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poor musculoskeletal and quality-of-life outcomes.[15-17] The delay 
in intravenous therapy can be mitigated by teaching patients how to 
practise intravenous infusion in their home settings. Indeed, in many 
comprehensive treatment centres in SA, patients are taught self-
infusion at an early age.[4] It has now been shown in many studies that 
intravenous infusion skill combined with early replacement therapy 
has the potential to limit bleed-induced musculoskeletal damage, 
limit the extent of blood loss, and improve bleed resolution and 
quality of life of haemophilia patients.[18-21] Recent data also indicate 
that early home-based therapy is cost-effective, and is associated with 
reduced pain and disability, decreased school and work absenteeism, 
and reduced hospitalisation rates.[22-24] Consequently, in many parts of 
the world, haemophilia patients are allowed to take CFC at home in 
order to infuse themselves prophylactically or to self-administer early 
during an acute bleeding episode.
In a survey performed in 10 haemophilia treatment centres in 
SA, the practice of home therapy varied from 0% to70%. Part of 
the explanation for this wide variability in practice is that there 
was no consensus among the healthcare providers on a number of 
questions on home therapy-related issues for patients with inherited 
bleeding disorders. The unanswered questions include: (i) who 
should be allowed to take CFC home in order to self-infuse; (ii) what 
the barriers to home therapy would be; (iii) what the criteria for 
identifying patients for home therapy should be; (iv) what the 
characteristics of products for use in the home setting should be; 
(v) what kind of support would be required for patients on home 
therapy; and (vi) how the effectiveness of home therapy should be 
monitored.
The Delphi approach is an established method for consensus building 
by using a series of reiterated questionnaires to facilitate a panel of 
selected experts to reach agreement on a particular subject.[25,26] The 
Delphi approach differs from standard surveys by asking the question as 
what should/would be, as opposed to surveys, which ask the question as 
what is.[27] It is particularly appropriate to use the Delphi method in rare 
diseases such as haemophilia for which prospectively generated data 
might take time or be difficult to collect, and particularly for questions 
that would be impractical to answer via other forms of research.[28] 
The Delphi method has frequently been used in haemophilia to reach 
expert consensus on a variety of issues.[29-32]
Objectives
This study used a modified Delphi method to seek consensus among 
haemophilia experts on key factors required for a successful home 
therapy programme for patients with inherited bleeding disorders 
in SA.
Methods
Study participants
Invited participants had expertise and knowledge in the care of 
patients with haemophilia and included medical practitioners, nurse 
practitioners and allied healthcare workers practising in haemophilia. 
They were representative of the haemophilia fraternity in SA in terms 
of expertise, experience, haemophilia population they cared for, and 
healthcare professions.
Study design and interventions
The Delphi method was administered by an independent facilitator 
in three rounds.
Round 1
In a face-to-face meeting, the objective and procedures were 
outlined to all participants. Participants were assigned to two groups 
and tasked to identify all haemophilia patient-, home setting-, 
healthcare provider-, treatment centre- and healthcare system-related 
factors involved in implementation of a successful home therapy 
programme. Participants considered each factor identified and the 
rationale for its inclusion. They were not allowed to give individual 
opinions, recommendations or consensus at this stage. All inputs 
were examined by the whole group in order to clarify possible 
ambiguous statements and remove duplicates.
The resultant list of issues on haemophilia home therapy was 
then formulated into questions, which were captured in a study 
questionnaire. The questionnaire was checked by a small core group 
of participants for completeness, consistency and clarity before being 
finalised. Care was taken that the statements were not rated or ranked 
at this stage.
Round 2
The finalised questionnaire was distributed to all participants through 
an online tool provided by McMaster University in Canada. Each 
participant received an invitation to complete the online questionnaire 
individually. Participants were not allowed to confer or discuss their 
input with each other. The timeline for completion of the survey was a 
maximum of 5 days after the first notification. At the end of 5 days, all 
responses were centrally collated, analysed and interpreted.
Round 3
Consensus statements from round 2 were used to proceed to 
round 3. All participants were asked to rank the statements in order 
of importance. The results were collated and checked for the level of 
agreement or disagreement among the participants.
Consensus was defined as ≥70% of the participants agreeing 
or disagreeing on a statement. Once consensus was reached, the 
statements were ranked from most to least important based on the 
rank received. The participant responses were collated, analysed and 
interpreted.
Results
Participant demographics
There were 20 participants who took part in the first meeting of 
the group, and the same number remained throughout the entire 
consensus process without dropouts. The demographic profile of the 
study participants is shown in Table 1. Our participating healthcare 
providers were all experienced in haemophilia care, with 18 of the 20 
having ≥6 years of working in haemophilia care.
Participant response rate and consensus
The participant response rate in round 2 and round 3 was 100%, 
reflecting the commitment of this group to the process. In round 2, 
consensus was reached in 33 of the 36 questions (92%).
The top three statements for which there was 100% expert 
agreement are listed in Table 2. The three statements for which there 
was no agreement among the study participants are listed in Table 3. 
There was general agreement for the remainder of the questionnaire 
statements, which are listed in Table 4. The consensus group 
identified several potential barriers to home therapy, and the top 10 
of these are listed in Table 5.
Discussion
Our study participants all agreed that home therapy should target 
the paediatric population as a priority over the adult population, that 
patients on home therapy should sign an informed consent and an 
indemnity, and that patients on home therapy should have round-
the-clock access to a healthcare provider (Table 2).
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As indicated in Table 1, a high proportion of participants in the 
group looked after paediatric patients, which may have skewed the 
consensus in favour of children. However, there were sufficient non-
paediatric participants to have changed this if there was no consensus. 
The rationale for targeting the paediatric group is the impact home 
therapy will have in preventing and reducing the haemophilia disease 
burden in this age group. Owing to poor venous access, many home 
therapy guidelines do not specifically recommend targeting the 
paediatric group for home therapy.[33-35] In a resource-constrained 
setting such as ours, our group considered the cost-effectiveness of 
home therapy in terms of volume of CFC to keep at home, as well as 
the long distances our patients have to travel to reach haemophilia 
treatment centres. In general, paediatric patients require fewer vials 
of CFC at home, and more than 10 of the 18 haemophilia treatment 
centres in SA are servicing patients drawn from rural settings.
The recommendation that patients on home therapy should sign 
an informed consent and an indemnity came as no surprise. SA is 
not a litigious society; however, we have seen a steep rise in health-
related litigations, particularly in state facilities where patients claim 
professional negligence.[36] This recommendation is also in line with 
increasing societal demands for the practice of ethical medicine in 
SA and aligns with current hospital practice for patients undergoing 
procedures to sign indemnity for hospitalisation and consent for 
all procedures. Once implemented, this recommendation will give 
patients and healthcare providers the reassurance that home therapy 
is taken as seriously as any other procedures performed in healthcare 
facilities.
The above fact links to the third top recommendation, that patients 
on home therapy should have round-the-clock access to a healthcare 
provider. Such support is already provided for all haemophilia 
patients, but becomes mandatory for patients who will be infusing 
CFC at home, in view of potential complications of poor venous 
access.
The participant experts in this Delphi process comprised 
10  doctors, 9 nurses and a physiotherapist. The equal number of 
doctor and non-doctor participants in this expert sample reflects 
the kind of collective decision-making that takes place in the care of 
patients with haemophilia. While other members of the haemophilia 
comprehensive care team were considered for inclusion, these panel 
members were thought to be pivotal in the direct management of 
haemophilia patients on home therapy. Unlike other Delphi processes 
in haemophilia, which have often excluded nurses,[29,32] our process 
included nurses, as they are critical role players in the instruction of 
patients on home therapy as well as in their follow-up and treatment 
monitoring.
Our participating healthcare providers were all experienced in 
haemophilia care, with 18 of the 20 having ≥6 years of working in 
haemophilia care. This is important, as the decisions taken on home 
therapy have lifelong implications for patients and their caregivers 
and therefore require considerable experience and knowledge in 
the haemophilia field. Our Delphi participants did not include 
administrators or patients, as healthcare providers wanted to 
reach consensus among themselves before including patients and 
administrators in the medical decision-making.
The Delphi process participants did not reach consensus on 3 
of the 36 statements in the questionnaire. The reasons for failing 
to reach consensus are fairly clear and reflect the influence of the 
composition of the group and the age and size of patients they look 
after. With regard to needle size, the non-consensus ultimately 
became a disagreement between paediatricians and adult treaters. In 
the final analysis, this disagreement was an academic exercise, as all 
CFC comes with pre-packed needles of the same size. On the home 
environment, paediatricians felt strongly that only knowledgeable, 
motivated and skilled caregivers should be allowed to participate in 
the home therapy programme. How much CFC patients take home 
is ultimately at the discretion of each hospital, and their policy is 
often informed by whether the patient is on episodic or prophylactic 
treatment. The generally accepted principle is for patients to have 
enough CFC to treat at least one bleed at home or to have enough 
CFC not to miss prophylactic doses until the next scheduled 
treatment centre visit. Current national and international guidelines 
are silent on these two aspects.[37,38]
Table 1. Demographic profile of the Delphi process 
participants
n
Number of participants 20
Participant professions
Doctor 10
Nurse 9
Physiotherapist 1
Experience in haemophilia care (years)
≤5 2
6 - 10 6
11 - 15 4
16 - 20 4
>20 4
Type of practice
Adult haemophilia only 3
Paediatric haemophilia only 7
Combined adult/paediatric 10
Number of haemophilia patients in the practice
20 - 100 12
101 - 200 2
201 - 300 1
301 - 400 1
401 - 500 2
>500 2
Table 2. Top three questionnaire statements for which there was 100% agreement among participants
• Treatment centres should prioritise paediatric patients for home therapy
• Patients on home therapy should sign informed consent and indemnity for participating in the home therapy programme
• Patients on home therapy should be provided with 24-hour round-the-clock support by the treatment centre
Table 3. Questionnaire statements for which there was no participant consensus
• The home environment most suitable for home therapy
• Sizes of needles supplied to people with haemophilia for home therapy
• Number of doses to be dispensed for home therapy
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Table 4. Statements of consensus among participants (>70% agreement per statement)
Questionnaire statement Agreement reached
1. Definition of home therapy • Home therapy is therapy taken by haemophilia patients at home under 
supervision of the haemophilia care team
2. Goals and rationale for implementing home therapy 
need to be defined
• The primary goals of home therapy should be to treat bleeds early or to 
put patients on prophylaxis in order to reduce bleed rates and associated 
musculoskeletal complications
3. Age of starting home therapy • Home therapy should be started as soon as the caregivers and patients have 
been instructed on intravenous infusion and deemed competent
4. Factors to consider before starting home therapy • Having a fridge to store product at home
• Supportive and nurturing home setting
• Hygiene conditions at home
• Privacy at home
• Distance of home from hospital
• Ability to contact the treatment team
5. Patient characteristics that should favour home therapy • Patients should be competent in IV needle insertion
• Patients should be reliable and trustworthy
• Patients should be able to identify the complications of IV needle insertion
• Patients should understand the importance of a sterile field when inserting 
the IV needle
• Patients should be able to dispose of needles safely
• Patients must have passed at least one course on home therapy
6. Issues of venous access in the home setting • Central venous and arterial lines should be avoided
• A maximum of three unsuccessful venous stabs should require expert 
intervention
7. Success indicators for home therapy • Should include evaluation of annualised bleeding rate
• Number of missed injections for patients on prophylaxis
• Serial measurement of musculoskeletal haemophilia complications
• Number of deaths of patients on home therapy
• Improvement in the quality of life of patients
8. Patients needing particular attention in the home 
therapy programme
• Poor venous access
• Inhibitor patients requiring bypassing agents
• Poor home support structure
• Non-compliant patients
• Patients who have failed home therapy training
• Patients unable to handle and store clotting factor concentrate
9. Important role players required for the support patients 
on home therapy
• Immediate parent/guardian/spouse
• Extended family
• Friends and neighbours
• Teachers and co-workers
• Local clinic sisters
• Emergency personnel
10.  Characteristics of haemophilia centres practising 
home therapy
• Ability to supply unlimited quantities of factor
• Availability of staff 24 hours a day to support patients
• Adequate treatment centre drug stock level
• Ability to monitor and review treatment compliance
• Ability to monitor home therapy impact and outcomes
• Ability of the treatment centre to train and monitor patients
11.  Characteristics of products used in the home therapy 
programmes
• The product should be non-thrombotic
• The product should be non-immunogenic in previously untreated patients
• The product should not be associated with allergy or anaphylaxis
• The product should not cause local reaction on skin extravasation
• Product overdose should be very well tolerated
12. Factors to consider when monitoring home therapy • Volume of product consumption and accountability
• Number of bleeds in a patient on prophylaxis
• Number of doses required to treat a bleeding episode
• Number of times the patient has run out of medication
• Number of calls the patient makes to the healthcare providers
IV = intravenous.
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There was non-unanimous but significant consensus among the 
Delphi group members on the remaining statements listed in Table 4. 
These statements will have the potential for informing policymaking 
and becoming part of standard operating procedures for all treatment 
centres in SA. The standardisation of procedures and policies will 
help reduce the current largely discrepant practices of home therapy 
healthcare providers.
To our knowledge, this study is the first to examine home 
therapy closely and to seek consensus among haemophilia healthcare 
providers in the developing world. The reasons for lack of similar 
studies in the past remain unclear, but could include the fact that 
expertise in haemophilia in many resource-constrained settings 
is limited and the very practice of home therapy might be poorly 
supported. In contrast, in many developed countries home therapy is 
regarded as part of the standard of care of haemophilia, and the need 
for consensus to implement it therefore does not exist.
The recommendations on home therapy would have been 
incomplete without identifying potential barriers and hurdles to 
its implementation. The biggest barrier identified from this Delphi 
process was the healthcare provider being the resource gatekeeper 
and not allowing patients to self-infuse. We managed to keep our 
Delphi process free of interference from the healthcare facility 
administrators, yet there were a number of haemophilia treatment 
centres in which patients who were adequately trained on home 
therapy were not allowed to take CFC to infuse themselves at home 
by either their healthcare team or hospital administrators. It is hoped 
that raising awareness around this practice will result in rational 
decision-making and alignment of the dispensing practice with the 
recommendations of this study.
Study strengths and limitations
The study strengths included the cohesiveness of the group, illustrated 
by the fact that none of the participants were lost during the study. 
The fact that consensus within the group was reached quickly within 
two iterations indicated the general convergence of thinking within 
the group, which it is hoped will translate to uniform policy and 
practice in SA.
The study had some limitations. The participants were self-selected 
and therefore may not be representative of haemophilia healthcare 
providers as a whole in SA. They included only a small number of 
healthcare providers and did not include patients or administrators, 
who would have provided a non-healthcare provider perspective to 
the consensus statements.
Conclusions
Through a modified Delphi process, we have been able to answer a 
number of questions and reached consensus on haemophilia home 
therapy, including who should be prioritised for home therapy, the 
prerequisites for home therapy, and barriers to a successful home 
therapy programme. The adoption of home therapy in haemophilia 
will result in a number of desirable outcomes that include reduction 
in bleeding rates, reduction in musculoskeletal complication rates 
and improvement in quality of life.[39-41] The consensus statements 
arising from this Delphi process will serve as a foundation for 
formulating a home therapy national policy and for narrowing 
the wide home therapy practice gap currently seen among the 
haemophilia treatment centres in SA.
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